Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Study of ZGGS15 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05864573
Recruitment Status : Not yet recruiting
First Posted : May 18, 2023
Last Update Posted : May 18, 2023
Information provided by (Responsible Party):
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Brief Summary:
This is a multi-center, open-label, Phase 1 clinical study of ZGGS15 for the treatment of patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Biological: ZGGS15 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZGGS15 in Patients With Advanced Solid Tumors
Estimated Study Start Date : June 2023
Estimated Primary Completion Date : August 2024
Estimated Study Completion Date : August 2024

Arm Intervention/treatment
Experimental: ZGGS15 Biological: ZGGS15
ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.

Primary Outcome Measures :
  1. The incidence of dose-limiting toxicities (DLTs) [ Time Frame: Up to 21Days ]
    A DLT is defined as any of the following adverse events occurring from the first dose to the end of the first Cycle (21 days), unless the investigator deems that the AE is clearly related to the disease progression or definitely due to an external cause.

  2. The maximum tolerated dose (MTD) [ Time Frame: Up to 24 Months ]
    During the dose-escalation stage, if ≥ 2 patients in a dose group experienced DLTs, then the dose level will be considered to be an intolerable dose, and the previous lower dose will be considered to be the MTD.

  3. The recommended dose for subsequent study [ Time Frame: Up to 24 Months ]
    The recommended dose for the subsequent study will be based on the data of preliminary efficacy, safety, PK, receptor occupancy results and biomarker (for example, immune activation), etc. from the dose-escalation phase, and will be fully evaluated among the investigators and the sponsor. The recommended dose for subsequent study should have at least 6 evaluable patients.

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Up to 24 Months ]
    Disease control rate (DCR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.

  2. Duration of response (DOR) [ Time Frame: Up to 24 Months ]
    Objective Response Rate will be determined from investigator derived tumor assessments per RECIST v. 1.1.

  3. Disease control rate (DCR) [ Time Frame: Up to 24 Months ]
    Disease control rate (DCR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fully understand the study and voluntarily sign the informed consent form;
  • Male or female, 18-70 years of age;
  • Histologically or cytologically confirmed diagnosis of advanced solid tumors, in whom the available standard treatments failed;
  • Must have at least 1 measurable lesion per RECIST v1.1;
  • Eastern Cooperative Oncology Group performance status of 0 or 1;
  • Life expectancy ≥ 3 months;
  • All adverse events from prior treatment have either returned to baseline or CTCAE v5.0≤Grade 1;
  • Both male and female participants (unless postmenopausal, surgical sterilization) and partners must agree to use a reliable form of contraception during the study treatment period and for at least 6 months after the last dose of the study drug.

Exclusion Criteria:

  • Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate the existence of the central nervous system (CNS) metastases;
  • Uncontrollable third cavity effusion requiring repeated drainage, which was judged by the investigator to be unsuitable for study;
  • The main organ function meets any of the following criteria within 7 days prior to treatment:

    • Hematological function: absolute neutrophil count (ANC) < 1.5 × 10^9/L, platelet (PLT) < 75 × 10^9/L, or hemoglobin (Hb) < 100 g/L;
    • Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 3 × upper limit of normal (ULN), ALT and AST ≥ 5×ULN for patients with liver metastases; total bilirubin (TBIL) ≥ 1.5×ULN; albumin < 30 g/L;
    • Blood cholesterol > 300 mg/dL or > 7.75 mmol/L;
    • Creatinine clearance (Cockcroft-Gault formula) < 50 mL/min;
    • International normalized ratio (INR) > 1.5 or activated partial thromboplastin time (APTT) > 1.5×ULN;
  • Any other malignancy within 5 years;
  • Abnormal thyroid function with clinical symptoms or diabetes, which cannot be controlled by available treatments;
  • History of autoimmune disease, including but not limited to systemic lupus erythematosus, nephritis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis;
  • Previous immune checkpoint inhibitors induced ≥ Grade 2 immune-related adverse reactions in vital organs, including but not limited to myocarditis and central nervous system toxicity; rapidly tumor progressed after previous PD-1 inhibitor treatment;
  • Interstitial lung disease, non-infectious pneumonitis, and radiation-induced pneumonia with symptoms and/or requiring steroids for treatment;
  • Received prior allogeneic stem cell transplantation or solid organ transplantation;
  • Active infection within 1 week before the first administration currently requires systemic anti-infective therapy;
  • Known allergy to other mAbs or any antibody excipient, severe allergic reaction to humanized antibodies or fusion proteins, and history of anaphylactoid reaction or other hypersensitivity reactions;
  • Known history of diagnosed neurological or mental disorders, for example, epilepsy, dementia, etc.;
  • Patients were deemed unsuitable for participating in the study by the investigator for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05864573

Layout table for location contacts
Contact: Siqi Jia +86-0512-57018310

Layout table for location information
China, Zhejiang
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact: Ji Zhu         
Sponsors and Collaborators
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Layout table for investigator information
Principal Investigator: Ji Zhu Zhejiang Cancer Hospital
Layout table for additonal information
Responsible Party: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Identifier: NCT05864573    
Other Study ID Numbers: ZGGS15-001
First Posted: May 18, 2023    Key Record Dates
Last Update Posted: May 18, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms